Pathology

Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review

Retrieved on: 
Mercoledì, Maggio 8, 2024
Neurodegenerative disease, Neuroimaging, MSA, Safety, Pharmacokinetics, Food, ASX, Pathology, Disease, Data monitoring committee, Patient, DMC, Biomarker, Clinical trial, Therapy, ATH, Food and Drug Administration, SAN, Pharmaceutical industry

MELBOURNE, Australia and SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an independent Data Monitoring Committee (DMC) has completed its third review of trial data and recommended the ATH434-201 Phase 2 study continue as planned. The ATH434-201 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage multiple system atrophy (MSA), a rare neurodegenerative disease with no approved treatments to slow or stop its progression.

Key Points: 
  • The DMC conducted its prespecified review of unblinded clinical data from study participants.
  • The plan for the DMC to review clinical data from the trial has been cleared with the U.S. Food and Drug Administration.
  • “We are pleased to report that the Data Monitoring Committee for our ATH434-201 Phase 2 clinical trial has again determined that there are no safety concerns and that the study can continue as planned,” said David Stamler, M.D., Chief Executive Officer of Alterity.
  • Additional information on the Phase 2 trial can be found by ClinicalTrials.gov Identifier: NCT05109091 .

Optimizing Deep Brain Stimulation for Obsessive-Compulsive Disorder - A Free Webinar from the Brain & Behavior Research Foundation

Retrieved on: 
Martedì, Maggio 7, 2024
Electrode, OCD, Obsessions, Pathology, Psychiatry, Patient, Brain, Deep brain stimulation, Assistant, Biomarker, Therapy, Quality of life

New York, May 07, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Optimizing Deep Brain Stimulation for Obsessive-Compulsive Disorder” on Tuesday, May 14, 2024, at 2:00 pm ET.

Key Points: 
  • New York, May 07, 2024 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) is hosting a free webinar, “Optimizing Deep Brain Stimulation for Obsessive-Compulsive Disorder” on Tuesday, May 14, 2024, at 2:00 pm ET.
  • Jeffrey Borenstein, M.D., President & CEO of the Brain & Behavior Research Foundation, and host of the public television series Healthy Minds is the webinar host.
  • Register today at BBRFoundation.org
    Obsessive-compulsive disorder (OCD) is a long-lasting disorder in which a person experiences uncontrollable and recurring thoughts (obsessions), engages in repetitive behaviors (compulsions), or both.
  • Treatment success, however, depends in part on personalized adjustment of deep-brain stimulation after the electrodes have been implanted.

Azra AI Appoints John Marshall as New CEO

Retrieved on: 
Mercoledì, Maggio 8, 2024
Data Management, Technology, Managed Care, Other Health, Health, Oncology, Health Technology, Software, Artificial Intelligence, Hospitals, Internet, Cancer, ROI, Azra, Hospital, Pathology, Artificial intelligence, Software as a service, History, IPO, Radiology, Medical Education Number, Patient, Acquisition, Data management, Multimedia, Internationalized domain name

Azra AI , a healthtech leader harnessing artificial intelligence (AI) and workflow automation to accelerate the identification and treatment of cancer, is thrilled to announce the appointment of John Marshall as its new Chief Executive Officer.

Key Points: 
  • Azra AI , a healthtech leader harnessing artificial intelligence (AI) and workflow automation to accelerate the identification and treatment of cancer, is thrilled to announce the appointment of John Marshall as its new Chief Executive Officer.
  • Marshall will succeed Chris Cashwell, who will continue to support Azra as an advisor.
  • "Given the increasing demand for AI-driven healthcare solutions, John Marshall is the ideal leader to propel Azra AI to new heights.
  • With John Marshall's strategic leadership and focus on expanding the platform's innovative capabilities, Azra AI will continue to drive impactful improvements in operational efficiency, patient care, and service line growth across the healthcare industry.

Marwood Group Hires Nayan Ghosh to Head Life Sciences & HealthTech Practice

Retrieved on: 
Mercoledì, Maggio 8, 2024
Health, Health Insurance, Nayan, FDA, Policy, Commercial, Pathology, Depression, Disease, Patient, Diagnosis, Therapy, Growth, Head, Pharmaceutical industry

Marwood Group , a leading, global healthcare advisory firm known for its deep expertise at the intersection of healthcare policy and commercial strategy, announced today the appointment of Nayan Ghosh as Director, Head of Life Sciences & HealthTech.

Key Points: 
  • Marwood Group , a leading, global healthcare advisory firm known for its deep expertise at the intersection of healthcare policy and commercial strategy, announced today the appointment of Nayan Ghosh as Director, Head of Life Sciences & HealthTech.
  • After first joining Marwood in 2017 to help expand the market access and commercial strategy capabilities of the Life Sciences & HealthTech practice , Ghosh took a hiatus in 2021 to serve as Head of Commercial & Regulatory Strategy at Arcade Therapeutics, targeting some of the first FDA authorizations for non-drug anxiety and depression treatments.
  • “Over the last decade, Marwood’s focus on Life Sciences & HealthTech has grown significantly, driven by its synergy with Marwood’s deep expertise, data and analytics capabilities related to healthcare services and delivery.
  • “The mission of Marwood’s Life Sciences & HealthTech practice is to help life-changing healthcare innovations get into the hands of the patients and practitioners who need them,” said Ghosh.

Cache Raises Seed Financing to Advance its Biomolecule Storage Technologies

Retrieved on: 
Martedì, Maggio 7, 2024
Technology, Research, Genetics, Health Technology, Biotechnology, Health, Data Management, Other Science, Science, Pillar, Harvard University, University, Cancer, Cache, International Society, American College, Cell, Laboratory, AUC, Harvard Business School, University Health Network, Biological engineering, Genetic, Software, Biophysical environment, Area studies, Biochemistry, RNA, Doctor of Philosophy, University Medical Center, Pathology, San Francisco Bay Area, Intelligence, ACMG, Stanford University, George Church, Bioethics, Chemistry, Faculty, MIT, MBA, SBIR, Yale School of Management, Temperature, Ageing, National Science Foundation, Dicarboxylic acid, Biology, Medical genetics, Nucleation, Computer data storage

Cache DNA, Inc. , a life sciences company revolutionizing biological sample and data storage infrastructure, today announced the closing of its seed round.

Key Points: 
  • Cache DNA, Inc. , a life sciences company revolutionizing biological sample and data storage infrastructure, today announced the closing of its seed round.
  • The funds will help power R&D and support commercial development efforts and key partnerships to bring their solutions to market.
  • “Over the past three decades, sequencing technologies have evolved drastically.
  • It feels like every month, a new sequencing method is developed,” says Michael Becich, Cache CEO.

South Africa Funeral Services Report 2024, with 22 Company Profiles Including AVBOB, Doves, Martin's Funerals, Icebolethu, Total Funeral Logistics, Calgro M3 and Independent Crematoriums SA - ResearchAndMarkets.com

Retrieved on: 
Martedì, Maggio 7, 2024
Religion, SME, Policy, Cremation, Death, Pathology, Culture, Funeral, Pressure, Private sector, Burial, Government, Funeral home, Growth, Cemetery, Life insurance

The "Funeral Services and Related Activities in South Africa 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Funeral Services and Related Activities in South Africa 2024" report has been added to ResearchAndMarkets.com's offering.
  • A global research study identified South Africa as the fourth most expensive country in terms of funeral costs, which were 3% above the global average.
  • The South African Funeral Practitioners Association has called on government to regulate the funeral services sector.
  • This report focuses on the funeral services and related activities sector in South Africa.

14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding

Retrieved on: 
Lunedì, Maggio 6, 2024
Oncology, Health, Technology, Health Technology, Genetics, Artificial Intelligence, Biotechnology, RUO, University, Prostate, NCCN, RC, International, RP, Risk, Grade, American Urological Association, Survival, Neoadjuvant therapy, PSA, Columbia University, Integration, Research, Pathology, GSC, Prostate cancer, Prostate-specific antigen, University of Michigan, Patient, NOC, Urology, Intelligence, AUA, MRI, Biopsy, Gene expression, Diagnosis, MUSIC, Waiting, Bladder cancer, Radical, Medical imaging

(Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from 14 presentations at AUA 2024, the annual meeting of the American Urological Association, show that the Decipher Prostate and Decipher Bladder Genomic Classifiers provide better prognostic information for patients with prostate and bladder cancer, compared to standard approaches.

Key Points: 
  • (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from 14 presentations at AUA 2024, the annual meeting of the American Urological Association, show that the Decipher Prostate and Decipher Bladder Genomic Classifiers provide better prognostic information for patients with prostate and bladder cancer, compared to standard approaches.
  • They also show that the research-use-only Decipher GRID (Genomic Resource for Intelligent Discovery) tool is helping to advance scientific understanding of these diseases.
  • Summary: The Decipher Prostate Genomic Classifier is associated with adverse pathology in patients eligible for Active Surveillance (AS) who were treated with radical prostatectomy (RP).
  • Podium Presentation PD42-03 : Understanding Population-Wide Genomic Risk Distribution and Integrating Clinical-Genomic Risk for Prognostication in Prostate Cancer.

AgroFresh to Host 12th Annual Post-Harvest Academy, Solidifying Position as Global Leader in Post-Harvest Solutions for Fresh Produce

Retrieved on: 
Mercoledì, Maggio 8, 2024
Washington State University, Plant pathology, Publication, Associate professor, Pathology, Acquisition, Database, Marketing, Associate

PHILADELPHIA, May 8, 2024 /PRNewswire/ -- AgroFresh Solutions, Inc., a global leader in post-harvest solutions for fresh produce, together with recently acquired Pace International, will host the 2024 Post-Harvest Academy on Wednesday, May 8, in Cle Elum, Washington. This year's invitation-only event will focus on the apple industry and feature leading industry voices from Washington State University among other distinguished presenters.

Key Points: 
  • PHILADELPHIA, May 8, 2024 /PRNewswire/ -- AgroFresh Solutions, Inc. , a global leader in post-harvest solutions for fresh produce, together with recently acquired Pace International , will host the 2024 Post-Harvest Academy on Wednesday, May 8, in Cle Elum, Washington.
  • This year's invitation-only event will focus on the apple industry and feature leading industry voices from Washington State University among other distinguished presenters.
  • Additional speakers include Desmond O'Rourke, President, Belrose, Inc., Simone Seifert-Higgins, Regulatory Manager, AgroFresh and Jim Spadafora, Director, Global Product Development, AgroFresh.
  • Belrose, Inc. is renowned for publications such as the World Apple Review, World Pear Review, World Kiwifruit Review and World Sweet Cherry Review.

Rady Children's Appoints Vijay A. Patel, MD, as Director of Pediatric Complex Sinus and Skull Base Surgery Program and Professor of Otolaryngology at UC San Diego

Retrieved on: 
Martedì, Maggio 7, 2024
University, Rady Children's Hospital, Hospital, Pediatric neurosurgery, Crystal skull, Doctor of Philosophy, Pathology, Patient, Physician, Child, Neurosurgery, SAN, Division, Head, UC, Nursing

SAN DIEGO, May 7, 2024 /PRNewswire/ -- Rady Children's Hospital-San Diego , one of the nation's top 10 pediatric health care systems, and the University of California San Diego are pleased to announce that Vijay A. Patel, MD, has been appointed as Director of the Pediatric Complex Sinus and Skull Base Surgery Program at Rady Children's Hospital and assistant professor of otolaryngology at UC San Diego School of Medicine.

Key Points: 
  • SAN DIEGO, May 7, 2024 /PRNewswire/ -- Rady Children's Hospital-San Diego , one of the nation's top 10 pediatric health care systems, and the University of California San Diego are pleased to announce that Vijay A. Patel, MD, has been appointed as Director of the Pediatric Complex Sinus and Skull Base Surgery Program at Rady Children's Hospital and assistant professor of otolaryngology at UC San Diego School of Medicine.
  • Dr. Patel will lead a multidisciplinary team of physicians committed to providing comprehensive care for pediatric patients with complex sinonasal and skull base lesions.
  • At Rady Children's, the Pediatric Complex Sinus and Skull Base Surgery Program offers an endoscopic endonasal approach that removes or alleviates the source of the problem while minimizing damage to surrounding critical structures.
  • "Rady Children's Hospital-San Diego and UC San Diego have long set the standard for pediatric health care on the West Coast and beyond," said Dr. Patel.

Dental Innovation Alliance VC Fund I, LP (DIA) Invests in Pearl, Pioneering AI in Dentistry

Retrieved on: 
Martedì, Maggio 7, 2024
FDA, Dental care, X-ray, AI, Dentistry, Practice management, DIA, Pathology, Artificial intelligence, Dentist, Partner (business rank), Health, Medical device

NEW YORK, May 7, 2024 /PRNewswire/ -- Dental Innovation Alliance VC Fund I, LP (DIA) announces a strategic investment in Pearl , a leading innovator in artificial intelligence (AI) solutions for dentistry.

Key Points: 
  • NEW YORK, May 7, 2024 /PRNewswire/ -- Dental Innovation Alliance VC Fund I, LP (DIA) announces a strategic investment in Pearl , a leading innovator in artificial intelligence (AI) solutions for dentistry.
  • DIA has closely monitored the AI sector, particularly for pathology detection and the evolving standard of care for dental practices worldwide.
  • Pearl's AI represents a significant advancement in dentistry, providing a seamless and less invasive approach to dental diagnostics.
  • In supporting Pearl's pioneering AI solutions, DIA reaffirms its commitment to driving transformative advancements within the dental and health technology sectors.